

JosÃ© M Carrascosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9223928/publications.pdf>

Version: 2024-02-01

235
papers

5,321
citations

81900

39
h-index

138484

58
g-index

270
all docs

270
docs citations

270
times ranked

4818
citing authors

#	ARTICLE	IF	CITATIONS
1	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1661-1669.	2.2	15
2	The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2110-2117.	2.2	4
3	Baricitinib for the treatment of atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2404-2413.	2.2	11
4	Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM. <i>Actas Dermo-sifiliográficas</i> , 2022, 113, 401-406.	0.4	1
5	Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Dermatologic Therapy</i> , 2022, 35, e15231.	1.7	17
6	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. <i>Actas Dermo-sifiliográficas</i> , 2022, 113, T261-T277.	0.4	4
7	Development of morphea during Nivolumab treatment. <i>Australasian Journal of Dermatology</i> , 2022, , .	0.7	0
8	[Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. <i>Actas Dermo-sifiliográficas</i> , 2022, 113, T401-T406.	0.4	2
9	Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00678.	1.3	4
10	Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. <i>Dermatology</i> , 2022, 238, 620-629.	2.1	4
11	Vegetative lesions associated with inhaled cocaine use. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1586-1588.	1.3	2
12	Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 941-953.	1.4	3
13	Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2878-2880.	2.2	4
14	Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. <i>British Journal of Dermatology</i> , 2022, 187, 817-820.	1.5	6
15	Aging in Male Wistar Rats Associates With Changes in Intestinal Microbiota, Gut Structure, and Cholecystokinin-Mediated Gut-Brain Axis Function. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1915-1921.	3.6	14
16	Definition of minimal disease activity in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 422-430.	2.4	11
17	Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e65-e67.	2.4	6
18	Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: a post hoc analysis through 64 weeks from reSURFACE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 919-927.	2.4	15

#	ARTICLE	IF	CITATIONS
19	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€”insights from a global registryâ€”based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136
20	Fototerapia en el prurigo nodular. Experiencia propia y revisi3n de la literatura. <i>Actas Dermo-sifilogrÃ¡ficas</i> , 2021, 112, 339-344.	0.4	3
21	Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 513-517.	1.2	26
22	The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 315-325.	3.0	11
23	Prevalence and stages of chronic kidney disease in psoriasis and psoriatic arthritis: A cross-sectional study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 321-321.	0.6	3
24	Drug Survival of IL-12/23, IL-17 and IL-23 InhibitorsÃ¢for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	6.7	65
25	Phototherapy for Prurigo Nodularis: Our Experience and a Review of the Literature. <i>Actas Dermo-sifilogrÃ¡ficas</i> , 2021, 112, 339-344.	0.4	3
26	Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1-11.	3.0	7
27	Aportaciones de un comitÃ© multidisciplinar para la prevenci3n de infecciones en pacientes tratados con inmunosupresores selectivos. <i>Medicina ClÃ¡nica</i> , 2021, 157, 489-494.	0.6	4
28	A New Classification of the Severity of Psoriasis: Whatâ€™s Moderate Psoriasis?. <i>Life</i> , 2021, 11, 627.	2.4	13
29	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderateâ€”toâ€”severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e709-e711.	2.4	2
30	Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. <i>Annals of Medicine</i> , 2021, 53, 1727-1736.	3.8	4
31	Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors. <i>Dermatology and Therapy</i> , 2021, 11, 2027-2042.	3.0	2
32	Contributions from a multidisciplinary committee for the prevention of infections in patients with targeted immunosuppressive therapy. <i>Medicina ClÃ¡nica (English Edition)</i> , 2021, 157, 489-489.	0.2	0
33	Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey. <i>Farmacia Hospitalaria</i> , 2021, 45, 240-246.	0.6	1
34	Effectiveness and safety of ustekinumab 90â€™%mg in patients weighing 100â€™%kg or less: a retrospective, observational, multicenter study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 222-226.	2.2	8
35	Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 344-351.	2.2	11
36	The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 738-741.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Informes de posicionamiento terapéutico: utilidad y transparencia. Actas Dermo-sifilográficas, 2020, 111, 3-6.	0.4	5
38	Manifestaciones cutáneas en el contexto de la infección por SARS-CoV-2 (COVID-19). Actas Dermo-sifilográficas, 2020, 111, 734-742.	0.4	30
39	Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm. Actas Dermo-sifilográficas, 2020, 111, 752-760.	0.4	6
40	Biosimilares en el tratamiento de la psoriasis. Actualización. Actas Dermo-sifilográficas, 2020, 111, 809-814.	0.4	8
41	Biosimilars in the Treatment of Psoriasis: An Update. Actas Dermo-sifilográficas, 2020, 111, 809-814.	0.4	0
42	Patch Testing During the COVID-19 Pandemic: Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC). Actas Dermo-sifilográficas, 2020, 111, 650-654.	0.4	1
43	The Use of Apremilast in Psoriasis: A Delphi Study. Actas Dermo-sifilográficas, 2020, 111, 115-134.	0.4	3
44	Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19). Actas Dermo-sifilográficas, 2020, 111, 734-742.	0.4	14
45	<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 495-498.	1.8	8
46	Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. Actas Dermo-sifilográficas, 2020, 111, 752-760.	0.4	1
47	Comorbilidades en dermatitis atópica: actualización y controversias. Actas Dermo-sifilográficas, 2020, 111, 481-486.	0.4	10
48	Recomendaciones del Grupo de Psoriasis de la AEDV sobre el manejo de la consulta de psoriasis durante la pandemia por COVID-19. Actas Dermo-sifilográficas, 2020, 111, 802-804.	0.4	9
49	Ichthyosiform eruption and facial erythema secondary to ponatinib therapy. JDDG - Journal of the German Society of Dermatology, 2020, 18, 743-747.	0.8	3
50	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1695-1706.	2.4	57
51	Pemetrexed-induced oedema of the eyelids and scalp in a patient with metastatic lung cancer. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e322-e324.	2.4	3
52	Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. Journal of Dermatological Treatment, 2020, 32, 1-8.	2.2	8
53	Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Journal of the American Academy of Dermatology, 2020, 83, 139-150.	1.2	37
54	Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2821-2829.	2.4	24

#	ARTICLE	IF	CITATIONS
55	Estudio Delphi para el uso de apremilast en la psoriasis. Actas Dermo-sifiliográficas, 2020, 111, 115-134.	0.4	8
56	Apremilast for psoriasis treatment. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 421-433.	0.8	7
57	Osteoporosis and Psoriasis. Actas Dermo-sifiliográficas, 2019, 110, 642-652.	0.4	3
58	Biosimilar and interchangeable: Inseparable scientific concepts?. British Journal of Clinical Pharmacology, 2019, 85, 2460-2463.	2.4	12
59	Women with moderate-to-severe psoriasis in Spain (<scp>BIOBADADERM</scp> registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. British Journal of Dermatology, 2019, 181, 1085-1087.	1.5	14
60	Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1214-1223.	2.4	8
61	Actinic lichen planus triggered by drug photosensitivity. Photodermatology Photoimmunology and Photomedicine, 2019, 35, 124-126.	1.5	8
62	Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. Journal of Dermatological Treatment, 2019, 30, 461-465.	2.2	27
63	Caloric restriction attenuates aging-induced cardiac insulin resistance in male Wistar rats through activation of PI3K/Akt pathway. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 97-105.	2.6	15
64	Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. Journal of Dermatological Treatment, 2019, 30, 424-429.	2.2	57
65	Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks. Journal of Dermatological Treatment, 2019, 30, 35-39.	2.2	12
66	Osteoporosis y psoriasis. Actas Dermo-sifiliográficas, 2019, 110, 642-652.	0.4	11
67	Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. Journal of Dermatological Treatment, 2018, 29, 806-811.	2.2	6
68	Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. Journal of the American Academy of Dermatology, 2018, 78, 798-800.	1.2	6
69	Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. Dermatology and Therapy, 2018, 8, 173-194.	3.0	45
70	New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Review of Clinical Immunology, 2018, 14, 259-273.	3.0	10
71	Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. Journal of Dermatological Treatment, 2018, 29, 140-144.	2.2	11
72	Study of insulin vascular sensitivity in aortic rings and endothelial cells from aged rats subjected to caloric restriction: Role of perivascular adipose tissue. Experimental Gerontology, 2018, 109, 126-136.	2.8	11

#	ARTICLE	IF	CITATIONS
73	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 334-346.	2.2	39
74	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. <i>Cellular and Molecular Immunology</i> , 2018, 15, 898-906.	10.5	17
75	Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2018, 109, 791-800.	0.4	12
76	Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis. <i>BioDrugs</i> , 2018, 32, 281-291.	4.6	15
77	Reacciones paradÃ³jicas de los tratamientos biolÃ³gicos utilizados en psoriasis: revisiÃ³n de la literatura. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2018, 109, 791-800.	0.4	34
78	Position statement for the management of comorbidities in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2058-2073.	2.4	61
79	Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. <i>British Journal of Dermatology</i> , 2017, 176, 797-799.	1.5	13
80	Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2017, 108, 52-58.	0.4	0
81	Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. <i>Biobadaderm registry. Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1021-1028.	2.4	8
82	Increase in minimal erythematol dose following oral administration of an antioxidant complex based on a mix of carotenoids: Double-blind, placebo-controlled trial. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2017, 33, 284-286.	1.5	7
83	Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1700-1708.	2.4	19
84	Fixed sunlight eruption: a new idiopathic photodermatosis rather than a variant of fixed drug eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2017, 33, 222-224.	1.5	3
85	Psoriasis e hÃ¡gado graso no alcohÃ³lico. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2017, 108, 506-514.	0.4	34
86	Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2017, 108, 800-808.	0.4	1
87	New treatments in psoriasis. <i>Medicina ClÃ¡nica (English Edition)</i> , 2017, 149, 157-159.	0.2	0
88	Implicaciones clÃ¡nicas, diagnÃ³sticas y terapÃ©uticas de la psoriasis y enfermedad cardiovascular. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2017, 108, 800-808.	0.4	10
89	Psoriasis y comorbilidad psiquiÃ¡trica: la prÃ³xima frontera. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2017, 108, 502-505.	0.4	4
90	Reliability of the MDi Psoriasis Application to Aid Therapeutic Decision-Making in Psoriasis. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2017, 108, 650-656.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Fiabilidad de una aplicación de ayuda a la toma de decisiones terapéuticas en el paciente con psoriasis (MDi Psoriasis 2.0). Actas Dermo-sifiliográficas, 2017, 108, 650-656.	0.4	5
92	Nuevos tratamientos en psoriasis. Medicina Clínica, 2017, 149, 157-159.	0.6	0
93	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. Dermatology and Therapy, 2017, 7, 265-279.	3.0	31
94	Phototoxic reaction to a combined oral contraceptive (levonorgestrel/ethinylestradiol). Photochemical and Photobiological Sciences, 2017, 16, 1381-1383.	2.9	9
95	Psoriasis and Psychiatric Disorders: The Next Frontier. Actas Dermo-sifiliográficas, 2017, 108, 502-505.	0.4	0
96	Psoriasis and Nonalcoholic Fatty Liver Disease. Actas Dermo-sifiliográficas, 2017, 108, 506-514.	0.4	17
97	Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm. Actas Dermo-sifiliográficas, 2017, 108, 52-58.	0.4	3
98	Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clinical Rheumatology, 2017, 36, 439-443.	2.2	20
99	Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians. Journal of Dermatological Treatment, 2017, 28, 188-199.	2.2	6
100	Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. Journal of Investigative Dermatology, 2017, 137, 313-321.	0.7	94
101	Immune-mediated inflammatory diseases differently affect IGRAs™ accuracy for latent tuberculosis infection diagnosis in clinical practice. PLoS ONE, 2017, 12, e0189202.	2.5	15
102	Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales (II). Actas Dermo-sifiliográficas, 2016, 107, 712-729.	0.4	12
103	Enfermedad renal y psoriasis. ¿Una nueva comorbilidad?. Actas Dermo-sifiliográficas, 2016, 107, 823-829.	0.4	8
104	Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II). Actas Dermo-sifiliográficas, 2016, 107, 712-729.	0.4	2
105	Photoinduced target-like drug reaction to naproxen. Photodermatology Photoimmunology and Photomedicine, 2016, 32, 323-326.	1.5	1
106	Kidney Disease and Psoriasis. A New Comorbidity?. Actas Dermo-sifiliográficas, 2016, 107, 823-829.	0.4	5
107	Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations. Actas Dermo-sifiliográficas, 2016, 107, 194-206.	0.4	8
108	Metotrexato en psoriasis moderada-grave: revisión de la literatura y recomendaciones de experto. Actas Dermo-sifiliográficas, 2016, 107, 194-206.	0.4	37

#	ARTICLE	IF	CITATIONS
109	Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. <i>Journal of Dermatological Treatment</i> , 2016, 27, 203-209.	2.2	15
110	Adhesion Molecules Associated with Female Genital Tract Infection. <i>PLoS ONE</i> , 2016, 11, e0156605.	2.5	4
111	Expert Recommendations on Treating Psoriasis in Special Circumstances. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2015, 106, 292-309.	0.4	1
112	Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2015, 106, 292-309.	0.4	9
113	Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 156-163.	2.4	57
114	Toll-like receptor 9 promoter polymorphism as a predictive factor of narrow-band UVB phototherapy response in patients with psoriasis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2015, 31, 98-103.	1.5	9
115	Hidradenitis suppurativa: nuevas oportunidades para una enfermedad dermatolÃ³gica huÃ©rfana. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2015, 106, 448-451.	0.4	4
116	Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. <i>Journal of Dermatological Treatment</i> , 2015, 26, 502-506.	2.2	29
117	Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 858-864.	2.4	47
118	Hidradenitis Suppurativa: New Opportunities for an Orphan Skin Disease. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2015, 106, 448-451.	0.4	0
119	Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2015, 106, 638-643.	0.4	9
120	Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2015, 106, 638-643.	0.4	0
121	Lupus erythematosus tumidus: a clinical and histological study of 25 cases. <i>Lupus</i> , 2015, 24, 751-755.	1.6	17
122	Body mass index in patients with moderate to severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 907-914.	2.4	62
123	Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. <i>European Journal of Dermatology</i> , 2014, 24, 662-669.	0.6	4
124	Prevalencia de la psoriasis en EspaÃ±a en la era de los agentes biolÃ³gicos. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2014, 105, 504-509.	0.4	89
125	Recommendations for the Coordinated Management of Psoriatic Arthritis by Rheumatologists and Dermatologists: A Delphi Study. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2014, 105, 216-232.	0.4	14
126	IL-17 in psoriasis. The final frontier or just another brick in the wall?. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2014, 105, 6-8.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Effects of age and caloric restriction on the cardiac and coronary response to endothelin-1 in rats. <i>Experimental Gerontology</i> , 2014, 60, 183-189.	2.8	5
128	Therapeutic implications of IL-17A blockade in psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 1-5.	0.4	0
129	Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1424-1430.	2.4	57
130	Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis. <i>Journal of Infection</i> , 2014, 69, 600-606.	3.3	16
131	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <scp>TRANSIT</scp> randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
132	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
133	Drug Survival in Biologic Therapy. Do We Know What it Means? Can We Calculate it?. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 729-733.	0.4	2
134	Realidades y retos de la fotoprotección en la infancia. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 253-262.	0.4	18
135	Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del paciente. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 128-134.	0.4	37
136	Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relación entre psoriasis y obesidad e implicaciones terapéuticas. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 31-44.	0.4	97
137	Elaboración mediante el método Delphi de recomendaciones para el manejo coordinado (reumatólogo/dermatólogo) de la artritis psoriásica. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 216-232.	0.4	24
138	Prevalence of Psoriasis in Spain in the Age of Biologics. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 504-509.	0.4	30
139	Sun Protection in Children: Realities and Challenges. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 253-262.	0.4	10
140	Supervivencia en terapia biológica. ¿Sabemos a qué nos referimos? ¿Podemos usarla?. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 729-733.	0.4	15
141	Effectiveness and Safety of Psoralen-UVA (PUVA) Topical Therapy in Palmoplantar Psoriasis: A Report on 48 Patients. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 418-425.	0.4	11
142	Adherence and Patient Satisfaction With Topical Treatment in Psoriasis, and the Use, and Organoleptic Properties of Such Treatments: A Delphi Study With an Expert Panel and Members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 488-496.	0.4	19
143	Guidelines for the Use of Acitretin in Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 598-616.	0.4	28
144	Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. <i>Archives of Dermatological Research</i> , 2013, 305, 105-112.	1.9	65

#	ARTICLE	IF	CITATIONS
145	Pityriasis rubra pilaris-like reaction induced by imatinib. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 520-522.	1.3	15
146	Inmunogenicidad en terapia biológica. Implicaciones en Dermatología. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 471-479.	0.4	33
147	Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 694-709.	0.4	32
148	Adherencia y satisfacción del paciente y características organolépticas y de uso de los tratamientos tópicos utilizados para la psoriasis: Consenso Delphi del panel de expertos y miembros del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 488-496.	0.4	43
149	<i>Actas Dermo-Sifiliográficas</i> , bilingüe en Pubmed. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 95.	0.4	0
150	Lipopolysaccharide-binding protein is increased in patients with psoriasis with metabolic syndrome, and correlates with C-reactive protein. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 81-84.	1.3	29
151	Safety and effectiveness of ustekinumab and antitumor necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. <i>British Journal of Dermatology</i> , 2013, 168, 609-616.	1.5	85
152	The Role of Fcγ3 Receptor Polymorphisms in the Response to Anti-Tumor Necrosis Factor Therapy in Psoriasis. <i>JAMA Dermatology</i> , 2013, 149, 1033.	4.1	38
153	Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy. <i>Archives of Dermatology</i> , 2012, 148, 463.	1.4	172
154	Mecanismo de acción de ustekinumab y su relevancia en la patogénesis de la psoriasis. Impacto en el sistema inmune. <i>Actas Dermo-sifiliográficas</i> , 2012, 103, 7-15.	0.4	0
155	Impairment of skeletal muscle insulin action with aging in Wistar rats: Role of leptin and caloric restriction. <i>Mechanisms of Ageing and Development</i> , 2012, 133, 306-316.	4.6	9
156	Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2012, 166, 1237-1244.	1.5	45
157	Age-associated development of inflammation in Wistar rats: Effects of caloric restriction. <i>Archives of Physiology and Biochemistry</i> , 2011, 117, 140-150.	2.1	37
158	BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 132-141.	0.4	4
159	Narrowband UV-B, Monochromatic Excimer Laser, and Photodynamic Therapy in Psoriasis: A Consensus Statement of the Spanish Psoriasis Group. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 175-186.	0.4	4
160	Clinical Characteristics and Disease Course in Patients Treated With Efalizumab Following Suspension of Marketing Authorization by the European Medicines Agency: A Multicenter Observational Study. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 354-364.	0.4	0
161	Development of Insulin Resistance During Aging: Involvement of Central Processes and Role of Adipokines. <i>Current Protein and Peptide Science</i> , 2011, 12, 305-315.	1.4	25
162	A black tongue in a young woman. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 429-430.	1.3	3

#	ARTICLE	IF	CITATIONS
163	Patch testing in children with hand eczema. A 5-year multicentre study in Spain. <i>Contact Dermatitis</i> , 2011, 65, 213-219.	1.4	33
164	El futuro se hace presente en fotoprotección solar. <i>Piel</i> , 2011, 26, 311-314.	0.0	2
165	CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis Severity. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1830-1837.	0.7	25
166	Commentary on European and British Guidelines for the Treatment of Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 285-290.	0.4	0
167	Guidelines on the Use of Methotrexate in Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 600-613.	0.4	10
168	Leukemia Cutis Arising at the Site of Injection of a Tetanus Vaccine Booster. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 727-729.	0.4	0
169	A new era in the management of psoriasis? The biologics: facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 81-87.	1.6	30
170	Comentarios a las directrices europeas y británicas sobre el tratamiento de la psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 285-290.	0.4	8
171	Metotrexato: guía de uso en psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 600-613.	0.4	65
172	The effect of aging on insulin signalling pathway is tissue dependent: Central role of adipose tissue in the insulin resistance of aging. <i>Mechanisms of Ageing and Development</i> , 2009, 130, 189-197.	4.6	29
173	Changes in the neuroendocrine control of energy homeostasis by adiposity signals during aging. <i>Experimental Gerontology</i> , 2009, 44, 20-25.	2.8	39
174	Generalized cutaneous drug eruption due to strontium ranelate. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 321-322.	2.4	7
175	Revisión actualizada del tratamiento tópico de la psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 190-200.	0.4	26
176	Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 277-286.	0.4	95
177	Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 386-413.	0.4	73
178	The expression of rat resistin isoforms is differentially regulated in visceral adipose tissues: effects of aging and food restriction. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 204-211.	3.4	20
179	Narrowband Ultraviolet B Therapy in Psoriasis: Reality, Outlook, and Uncertainty. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 3-6.	0.4	0
180	Update of the Topical Treatment of Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 190-200.	0.4	5

#	ARTICLE	IF	CITATIONS
181	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2009, 100, 386-413.	0.4	14
182	Characteristics of Patients With Hand Dermatitis Referred to the Contact Dermatitis Unit of a Tertiary Hospital and Impact of Patch Testing on Diagnosis. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2009, 100, 493-498.	0.4	1
183	Basal Cell Carcinoma. <i>Cancer Treatment and Research</i> , 2009, 146, 263-278.	0.5	8
184	Disseminated StrongyloidesÂstercoralis infection withÂaÂcutaneous presentation inÂanÂimmunosuppressed patient. <i>European Journal of Dermatology</i> , 2009, 19, 404-405.	0.6	2
185	Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1131-1134.	2.4	13
186	EFFECTS OF CHRONIC ACARBOSE TREATMENT ON ADIPOCYTE INSULIN RESPONSIVENESS, SERUM LEVELS OF LEPTIN AND ADIPONECTIN AND HYPOTHALAMIC NPY EXPRESSION IN OBESE DIABETIC WISTAR RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 256-261.	1.9	11
187	Reply to: â€œTreatment of Minor and Benign Skin Lesions in the Spanish Public Health System: Experience in Health Area 19 of the Autonomous Community of Valenciaâ€. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2008, 99, 234-235.	0.4	0
188	Acute dermal abscesses caused by <i>Serratia marcescens</i> . <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 891-893.	1.2	12
189	RÃ©plica: Â«PatologÃ¡a cutÃ¡nea benigna banal y sistema pÃºblico. Experiencia en el Departamento de Salud 19 de la Comunidad ValencianaÂ». <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2008, 99, 234-235.	0.4	0
190	Efectos adversos de la fototerapia: clÃ¡nica y manejo. <i>Piel</i> , 2008, 23, 447-452.	0.0	5
191	Impaired Central Insulin Response in Aged Wistar Rats: Role of Adiposity. <i>Endocrinology</i> , 2007, 148, 5238-5247.	2.8	45
192	Effect of age and moderate food restriction on insulin sensitivity in Wistar rats: role of adiposity. <i>Journal of Endocrinology</i> , 2007, 194, 131-141.	2.6	114
193	Consensus Document on Therapy With Bath Psoralen-UV-A. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2007, 98, 164-170.	0.4	0
194	Should Minor and Benign Cutaneous Lesions Be Treated by the Health Service?. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2007, 98, 236-239.	0.4	0
195	Effects of narrowband UV-B on pharmacodynamic markers of response to therapy: an immunohistochemical study over sequential samples. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 769-776.	1.3	22
196	Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. <i>British Journal of Dermatology</i> , 2007, 156, 24-29.	1.5	21
197	Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 828-829.	2.4	17
198	Treatment of Inverse Psoriasis with Excimer Therapy and Tacrolimus Ointment. <i>Dermatologic Surgery</i> , 2007, 33, 361-363.	0.8	18

#	ARTICLE	IF	CITATIONS
199	Letter: A Tattoo Reaction in a Sentinel Lymph Node from a Patient with Melanoma. <i>Dermatologic Surgery</i> , 2007, 33, 766-767.	0.8	19
200	Allergic contact dermatitis to 2-(thiocyano-methylthio) benzothiazole present in a packaging wood. <i>Contact Dermatitis</i> , 2007, 57, 121-122.	1.4	2
201	Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, .	2.4	0
202	A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 060703142021003-???	2.4	39
203	Altered subcellular distribution of IRS-1 and IRS-3 is associated with defective Akt activation and GLUT4 translocation in insulin-resistant old rat adipocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 197-206.	4.1	9
204	Narrow-band ultraviolet B in aquagenic pruritus. <i>British Journal of Dermatology</i> , 2005, 153, 1233-1234.	1.5	22
205	Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: modulation by aging and differentiation in rat adipose tissue. <i>Journal of Molecular Endocrinology</i> , 2005, 34, 153-161.	2.5	52
206	Leptin Impairs Insulin Signaling in Rat Adipocytes. <i>Diabetes</i> , 2004, 53, 347-353.	0.6	107
207	Isolation and biological characterization of a 6-kDa protein from hepatopancreas of lobster <i>Panulirus argus</i> with insulin-like effects. <i>General and Comparative Endocrinology</i> , 2003, 131, 284-290.	1.8	27
208	Ageing increases SOCS-3 expression in rat hypothalamus: effects of food restriction. <i>Biochemical and Biophysical Research Communications</i> , 2002, 296, 425-428.	2.1	87
209	Activation of MAP kinase by insulin and vanadate in adipocytes from young and old rats. <i>Molecular and Cellular Endocrinology</i> , 2002, 189, 77-84.	3.2	25
210	Long-term food restriction prevents ageing-associated central leptin resistance in wistar rats. <i>Diabetologia</i> , 2002, 45, 997-1003.	6.3	102
211	PÃ©pura. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2001, 8, 215-229.	0.0	0
212	Estrategias terapÃ©uticas en el prurigo nodular. <i>Piel</i> , 2001, 16, 360-364.	0.0	5
213	Decreased leptin uptake in hypothalamic nuclei with ageing in Wistar rats. <i>Journal of Endocrinology</i> , 2001, 171, 23-32.	2.6	79
214	An immunohistopathologic study in cutaneous necrotizing vasculitis. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 130-135.	1.3	17
215	Vanadate fully stimulates insulin receptor substrate-1 associated phosphatidyl inositol 3-kinase activity in adipocytes from young and old rats. <i>FEBS Letters</i> , 1998, 425, 298-304.	2.8	39
216	Changes in the Kinase Activity of the Insulin Receptor Account for an Increased Insulin Sensitivity of Mammary Gland in Late Pregnancy. <i>Endocrinology</i> , 1998, 139, 520-526.	2.8	22

#	ARTICLE	IF	CITATIONS
217	Papular acrodermatitis of childhood related to poxvirus and parvovirus B19 infection. <i>Cutis</i> , 1998, 61, 265-7.	0.3	30
218	Sequential Combined Therapy with Thaidomide and Narrow-Band (TL01) UVB in the Treatment of Prurigo nodularis. <i>Dermatology</i> , 1997, 195, 359-361.	2.1	55
219	Dideoxyinosine-Associated Ofuji Papuloerythroderma in an HIV-Infected Patient. <i>Dermatology</i> , 1997, 195, 410-411.	2.1	25
220	<i>In Vivo</i> Insulin-Dependent Glucose Uptake of Specific Tissues Is Decreased during Aging of Mature Wistar Rats. <i>Endocrinology</i> , 1997, 138, 49-54.	2.8	66
221	P-37: Role of the C-terminal domain of insulin receptor β^2 -subunit in aging: effects of truncation. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996, 104, 101-102.	1.2	4
222	Cutis Marmorata Telangiectatica Congenita or Neonatal Lupus?. <i>Pediatrics International</i> , 1996, 13, 230-232.	0.5	0
223	Impairment of the liver insulin receptor autoactivation cascade at full-term pregnancy in the rat. <i>Biochemical Journal</i> , 1995, 311, 523-529.	3.7	4
224	Papular-Purpuric Gloves-and-Socks Syndrome Related to Cytomegalovirus Infection. <i>Dermatology</i> , 1995, 191, 269-270.	2.1	59
225	Bacillary angiomatosis presenting as a malleolar ulcer. <i>Archives of Dermatology</i> , 1995, 131, 963-964.	1.4	6
226	Regulation of cyclic AMP synthesis and degradation is modified in rat liver at late gestation. <i>Biochemical Journal</i> , 1992, 286, 419-424.	3.7	3
227	Effect of aging on the kinetic characteristics of the insulin receptor autophosphorylation in rat adipocytes. <i>Archives of Biochemistry and Biophysics</i> , 1992, 296, 231-238.	3.0	20
228	Activation of phosphatidylinositol-3-kinase by insulin is mediated by both A and B human insulin receptor types. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 123-127.	2.1	17
229	The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. <i>Biochemical and Biophysical Research Communications</i> , 1991, 177, 1013-1018.	2.1	102
230	Short-term effect of glutamine on the incorporation of glucose-carbon into nucleic acids in Ehrlich ascites tumour cells. <i>Biochimie</i> , 1990, 72, 291-293.	2.6	1
231	Insulin receptor kinase activity in rat adipocytes is decreased during aging. <i>Biochemical and Biophysical Research Communications</i> , 1989, 160, 303-309.	2.1	30
232	Tyrosine kinase activity of liver insulin receptor is inhibited in rats at term gestation. <i>Biochemical Journal</i> , 1989, 263, 267-272.	3.7	16
233	An Mr 180000 protein is an endogenous substrate for the insulin-receptor-associated tyrosine kinase in human placenta. <i>Biochemical Journal</i> , 1987, 243, 797-801.	3.7	32
234	Evidence that (a) serine specific protein kinase(s) different from protein kinase C is responsible for the insulin-stimulated actin phosphorylation by placental membrane. <i>FEBS Letters</i> , 1986, 201, 81-86.	2.8	9

#	ARTICLE	IF	CITATIONS
235	Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. Cancer Research, 1984, 44, 3831-5.	0.9	73